Perampanel 4mg
Perampanel is a highly selective, noncompetitive AMPA type glutamate receptor antagonist. Perampanel was approved as adjunct therapy for focal-onset seizure in adults. It is highly protein bound (~ 95%); after oral administration it is almost completely absorbed and is converted via hepatic metabolism by CYP3A4 to an inactive metabolite, then excreted renally. Perampanel carries an FDA “black box warning” for adverse events including serious psychiatric, behavioral, mood, or personality changes, which may be life threatening. Additional adverse effects include dizziness, somnolence, headache, and ataxia. While perampanel has several attractive characteristics—a relatively novel mechanism of action and once-daily dosing—perampanel is considered a third-line therapy for epilepsy in the elderly at this time, given the risk of falls (Trinka et al., 2016), limited clinical experience, and lack of generic formulations.

Medicine are subject to availability and supply from the production company. The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice with a doctor. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.